Document Classification

Section Type: RESULTS

Text: Among the prespecified patient-reported outcomes (110 patients on gefitinib and 121 on placebo completed both baseline and 4 week questionnaires and were included in analyses), odynophagia was significantly better in the gefitinib group (adjusted mean difference -861, 95 % CI -1449 to -273 ; n = 227 ; p = 0004), whereas the other outcomes were not significantly improved compared with placebo : global quality of life (269, 95 % CI -233 to 772, n = 231, p = 0293), dysphagia (-318, 95 % CI -836 to 200, n = 231, p = 0228), and eating (-411, 95 % CI -996 to 175, n = 229, p = 0168).